Cited by 377RNA and protein synthesis mechanismsPI3K/AKT/mTOR signaling in cancerRNA modifications and cancer

Targeting the eIF4F Translation Initiation Complex: A Critical Nexus for Cancer Development

Open access
Pelletier, Jerry, Graff, Jeremy, Ruggero, Davide, Sonenberg, Nahum·2015·Cancer Research

Abstract

Elevated protein synthesis is an important feature of many cancer cells and often arises as a consequence of increased signaling flux channeled to eukaryotic initiation factor 4F (eIF4F), the key regulator of the mRNA–ribosome recruitment phase of translation initiation. In many cellular and preclinical models of cancer, eIF4F deregulation results in changes in translational efficiency of specific mRNA classes. Importantly, many of these mRNAs code for proteins that potently regulate critical cellular processes, such as cell growth and proliferation, enhanced cell survival and cell migration that ultimately impinge on several hallmarks of cancer, including increased angiogenesis, deregulated growth control, enhanced cellular survival, epithelial-to-mesenchymal transition, invasion, and metastasis. By being positioned as the molecular nexus downstream of key oncogenic signaling pathways (e.g., Ras, PI3K/AKT/TOR, and MYC), eIF4F serves as a direct link between important steps in cancer development and translation initiation. Identification of mRNAs particularly responsive to elevated eIF4F activity that typifies tumorigenesis underscores the critical role of eIF4F in cancer and raises the exciting possibility of developing new-in-class small molecules targeting translation initiation as antineoplastic agents. Cancer Res; 75(2); 250–63. ©2014 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-14-2789

Cites

220 of 220 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

2 retracted

Flagged first, then by citations

7 of the 227 references couldn’t be matched to a known paper.

Research works printed but not linked: 4

  1. [122]Wendel HG De Stanchina E Fridman JS Malina A Ray S Kogan S Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy Nature 2004 428 6980 332 7 15029198
  2. [127]Nasr Z Robert F Porco JA Jr Muller WJ Pelletier J eIF4F suppression in breast cancer affects maintenance and progression Oncogene 2013 32 7 861 71 22484424 PMC4863948
  3. [158]DeFatta RJ Nathan CA De Benedetti A Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line Laryngoscope 2000 110 6 928 33 10852506
  4. [195]Konicek BW Stephens JR McNulty AM Robichaud N Peery RB Dumstorf CA Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases Cancer research 2011 71 5 1849 57 21233335

Cited by

Sorted by citations

Authors
Pelletier, J., Graff, J., Ruggero, D., & Sonenberg, N.
Affiliations
  • Institut du cancer Rosalind & Morris Goodman (CA)
  • Eli Lilly (United States) (US)
  • University of California, San Francisco (US)
Corresponding author
Pelletier, Jerry
Venue
Cancer Research
Published
2015-01-14
Volume
75
Issue
2
Pages
250-263
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2005176113
Cited by
367
References
227
Citations by year
2026: 18 · 2025: 18 · 2024: 30 · 2023: 36 · 2022: 30 · 2021: 39 · 2020: 32 · 2019: 35 · 2018: 40 · 2017: 33 · 2016: 37 · 2015: 19
FWCI
4.17
Type
journal article
Language
en
Open access
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship@McGill (McGill) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • U.S. Public Health Service (MOP-106530, MOP-115126)
  • National Cancer Institute (R01CA140456, R01CA184624, R01CA154916)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
Keywords
eIF4F, translation initiation, cancer, translational regulation, oncogenic signaling, Ras, c-Myc, metastasis, epithelial-mesenchymal transition, angiogenesis, cell proliferation
MeSH terms
Animals, Antineoplastic Agents, Humans, Neoplasms, Eukaryotic Initiation Factor-4F, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review